Business
The Power Play by The Market Herald Releases New Interviews with Datametrex, Group Ten Metals, Algernon Pharmaceuticals and Alianza Minerals Discussing Their Latest News
VANCOUVER, BC / ACCESSWIRE / November 1, 2021 / The Power Play by The Market Herald has anno...
About this update from Silver North Resources Ltd.
[{"type":"text","content":"The Power Play by The Market Herald Releases New Interviews with Datametrex, Group Ten Metals, Algernon Pharmaceuticals and Alianza Minerals Discussing Their Latest NewsVANCOUVER, BC / ACCESSWIRE / November 1, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Datametrex, Group Ten Metals, Algernon Pharmaceuticals and Alianza Minerals discussing their latest press releases.The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.Datametrex (TSXV:DM) (OTCQB:DTMXF) subsidiary launches in-person patient careDatametrex subsidiary Medi-Call MD has launched in-person patient care services in Vancouver. Medi-Call is an enhanced telemedicine company providing technology-driven e-health and m-health care services. Marshall Gunter, CEO of Datametrex, spoke with Caroline Egan to discuss the news.For the full interview with Marshall Gunter and to learn more about Datametrex's announcement, click here.Group Ten Metals (TSXV:PGE) (OTCQB:PGEZF) announces inaugural MRE for the Stillwater West PGE-Ni-Cu-Co + Au ProjectGroup Ten Metals has released results from the first independent National Instrument 43-101 mineral resource estimate for its Stillwater West project in Montana. Highlights include inferred mineral resources totalling 2.4 million ounces of palladium, platinum, rhodium, and gold. Michael Rowley, Group Ten's President and CEO, sat down with Caroline Egan to discuss the results of the estimate.For the full interview with Michael Rowley and to learn more about Group Ten Metal's announcement, click here.Algernon Pharmaceuticals (CSE:AGN) (OTCQB:AGNPF) establishes optimum treatment period for DMT in neuron studyAlgernon Pharmaceuticals has established the optimum peak stimulation period for neuron outgrowth by AP-188 (DMT) in its pre-clinical in vitro study. This current data set is from the second part of Algernon's in vitro experiment designed to focus on the duration of infusion needed to achieve maximal cortical neuron outgrowth. Chris Moreau, CEO of Algernon Pharmaceuticals spoke with Caroline Egan to discuss the news.For the full interview with Chris Moreau and to learn more about Algernon Pharmaceuticals' announcement, click here.Alianza Mi...